Business Wire

Puma Biotechnology Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembrolizumab for Rb-Deficient Head and Neck Squamous Cell Carcinomas at the 2023 ...

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the poster presentation of a Phase I/II trial of alisertib plus pembrolizumab for the ...
FIRSTonline

Puma changes ownership: Chinese group Anta buys 29% stake from the Pinault family for €1,5 billion.

Anta Sports Products acquired a 29% stake in Puma from Artemis for €1,5 billion, becoming the German group's largest shareholder. Puma stock is rallying, marking a new phase for the German sportswear ...